New Trial: Rutazyme Capsules, 40 Adults, Obesity, 12 Weeks
Summary
A new clinical trial has been registered on ClinicalTrials.gov under identifier NCT07540949. The study will evaluate a lemon fermented product capsule (Rutazyme) for metabolic health in 40 adults aged 18-65 with obesity over 12 weeks. Participants will be randomised to receive either the active capsule or a placebo capsule daily.
What changed
This entry registers a new clinical trial on ClinicalTrials.gov. The study is a randomised, placebo-controlled trial assessing a lemon fermented product capsule (Rutazyme) for improvements in metabolic health markers in adults with obesity. Forty participants will receive either the active capsule or placebo daily for 12 weeks, with metabolic and safety laboratory measures monitored throughout.
Sponsors, investigators, and institutional review boards should note the trial registration for coordination and compliance with ClinicalTrials.gov reporting requirements. No compliance deadline or penalty is stated in the registration entry.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Rutazyme Lemon Fermented Product Capsules for Metabolic Function in Adults With Obesity
N/A NCT07540949 Kind: NA Apr 21, 2026
Abstract
This study evaluates whether a fruit- and vegetable-based fermented product (Rutazyme® lemon fermented product) taken as a capsule can improve metabolic health in adults with obesity. Forty adults aged 18-65 years with obesity (BMI ≥ 27 kg/m² and waist circumference > 90 cm for men or > 80 cm for women) will be randomly assigned to receive either a Rutazyme® lemon fermented product capsule (500 mg) or a placebo capsule once daily at bedtime for 12 weeks. Before supplementation, participants will complete a 2-week stabilization period during which they maintain their usual diet and physical activity.
Body composition and waist/hip measurements will be assessed during the study, and blood pressure will be monitored. Blood samples will be collected to evaluate metabolic and safety laboratory measures (e.g., lipids, glucose, insulin, inflammation markers, liver and kidney function), and stool samples will be collected to assess gut microbiota. Gut-brain axis biomarkers (GLP-1 and PYY) will be measured at multiple time points after capsule intake at baseline and at Week 12. The results will help determine the metabolic effects and safety of Rutazyme® lemon fermented product supplementation in adults with obesity.
Conditions: Obesity, Metabolic Syndrome
Interventions: Rutazyme® Lemon Fermented Product Capsule, Placebo Capsule (Maltodextrin; GLUCIDEX®12)
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.